Prompt Approval of Safe Generic Drugs Act
Latest Action
Referred to the House Committee on Energy and Commerce.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Prompt Approval of Safe Generic Drugs Act (H.R. 9616) is a legislative proposal introduced in the 118th Congress aimed at expediting the approval process for generic drugs deemed safe. The bill was referred to the House Committee on Energy and Commerce but did not advance further and is currently classified as failed or expired. The bill falls under the health policy area and seeks to address regulatory procedures related to generic drug approvals, although the full text and detailed provisions are not publicly available.
H.R. 9616 intended to speed up the approval of safe generic drugs but did not progress beyond committee referral and is now expired.
- The bill focuses on accelerating the approval process for generic drugs considered safe.
- It was introduced in the House and referred to the House Committee on Energy and Commerce on September 17, 2024.
- The bill did not advance beyond committee and is currently classified as failed or expired.
['Generic drug manufacturers seeking faster regulatory approval', 'Patients who may gain quicker access to affordable generic medications', 'Healthcare providers relying on generic drug availability', 'Regulatory agencies involved in drug approval processes']
['Lack of publicly available full bill text limits assessment of implementation details and enforcement mechanisms', 'Potential challenges in balancing expedited approval with ensuring drug safety and efficacy', 'Unclear funding or resource allocation for regulatory agencies to implement accelerated processes', 'Oversight provisions and accountability measures are not specified']
The bill was introduced during the 118th Congress and referred to the House Committee on Energy and Commerce, which oversees health-related legislation. The absence of further legislative action and its current failed or expired status indicate it did not gain sufficient support or priority to advance. The bill fits within ongoing congressional efforts to improve access to generic drugs and reduce healthcare costs.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential reduction in time to market for generic drugs could increase competition and lower drug prices.', 'Faster approvals might strain regulatory agency resources if not accompanied by increased funding or staffing.', 'Changes in approval timelines could impact pharmaceutical industry strategies and innovation incentives.']
Transparency is limited due to the absence of the full bill text and official summary. This restricts public and expert scrutiny of the bill’s specific provisions, enforcement mechanisms, and funding sources. Monitoring legislative progress and committee discussions would be necessary for a fuller understanding of the bill’s implications.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.